Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 189,713

Document Document Title
WO/2021/089764A1
The present invention relates to diagnostic methods to assess the presence of quorum sensing molecules (QSM), preferably peptides (QSPs), that influence muscle wasting in humans. The present invention furthermore relates to the use of th...  
WO/2021/092094A1
Provided herein are target HLA-PEPTIDE antigens, e.g., HLA-PEPTIDE neoantigens and shared tumor HLA-PEPTIDE antigens, and antigen binding proteins (ABPs) that bind the target HLA- PEPTIDE antigens. Also disclosed are methods for identify...  
WO/2021/067863A3
The present invention relates to targeted IL-12 heterodimeric Fc fusion proteins, where the fusion proteins bind to human PD-1 or human PD- L1.  
WO/2021/088219A1
Provided is an application of a TRPC1 peptide molecule in preparation of a drug for treating inflammation caused by viral infection, relating to the technical field of biomedicine. Studies show that a third extracellular domain polypepti...  
WO/2021/062124A3
Described herein are methods and compositions for the prevention or treatment of obesity and obesity-related disorders. The methods and compositions are based, inter alia, on the observations that OPN3 is the most highly expressed opsin ...  
WO/2021/090894A1
The present invention addresses the problem of providing a novel peptide capable of treating, preventing, or ameliorating a mood disorder. The present invention provides a peptide that has an amino acid sequence set forth in SEQ ID NO:...  
WO/2021/091881A1
A method of providing a high concentration disulfide-linked caspase inhibitor-cell penetrating peptide conjugate is described. The method includes incubating a caspase inhibitor having one or more thiol groups with a reducing agent selec...  
WO/2021/092354A1
Provided herein are methods and compositions related to the administration of uricase compositions and compositions comprising synthetic nanocarriers comprising an immunosuppressant for the treatment of subjects, including subjects with ...  
WO/2021/089554A1
The present disclosure relates to the use of a novel dosage form of merotocin in improving lactation in a female in need thereof. The disclosure particularly provides the use of a composition suitable for intranasal administration that p...  
WO/2021/092471A1
Provided herein are compositions comprising a vaccine composition and an agent that triggers metabolic reprogramming of B cells and methods of using the agent that triggers metabolic reprogramming of B cells to increase effectiveness of ...  
WO/2021/091997A1
The present application relates to compositions capable of inducing an immune response against Varicella zoster virus, methods of administering such compositions, and methods of producing such compositions.  
WO/2021/092382A1
A method of treating or preventing a microbial infection in a patient is provided, along with a wound irrigation system and a composition in the form of an irrigation liquid for reducing microbial load or preventing microbial infection i...  
WO/2021/091956A1
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.  
WO/2021/091317A1
The present invention relates to synthetic α-secretase (SAS) and a use thereof. According to the present invention, a synthetic α-secretase, which is a fusion protein comprising, as an active ingredient, NIa protease, a fragment thereo...  
WO/2021/092436A1
Methods and processes to identify neoplastic tissue antigens derived from alternative splicing (AS) are described, in accordance with various embodiments of the invention. Also described are novel tumor antigens that are useful as target...  
WO/2021/087839A1
Provided are a tumor-specific polypeptide sequence and an application thereof. The polypeptide comprises at least any polypeptide in a first peptide group, and can optionally comprise at least any polypeptide in a second peptide group. T...  
WO/2021/089736A1
The present invention relates to the treatment of muscular diseases.  
WO/2021/091304A1
The present invention relates to a novel human epidermal growth factor (hEGF)-trigger factor (TF) fusion protein and a use thereof. More particularly, the human epidermal growth factor (hEGF)-trigger factor (TF) fusion protein of the pre...  
WO/2021/090855A1
The following were discovered: a cyclic peptide compound that interacts with Ras; and an unnatural amino acid that is useful in the production of said cyclic peptide compound. The cyclic peptide compound was also discovered to inhibit bo...  
WO/2021/091316A1
The present invention relates to a composition, comprising TMEM176B as an active ingredient, for prevention or treatment of degenerative brain disease. A composition according to an embodiment promotes the phagocytic action of astrocytes...  
WO/2021/092140A1
A method of enriching Veillonellaand reducing lactate in the gut microbiome in a subject, comprising administering to the subject a therapeutically effective amount of a chimeric peptide sequence, thereby enriching Veillonella and reduci...  
WO/2021/062405A3
Methods comprising a step of administering, to a mammalian male subject, a composition comprising α-lactalbumin for the treatment of male breast cancer.  
WO/2021/090322A1
The present invention, in some embodiments, relates to a method of treatment, prevention or alleviation of Palmoplantar Keratoderma (PPK) in a patient in need thereof, comprising a debridement step followed by topical administration of a...  
WO/2021/092358A1
The present inventive concept is related to a modified follicle-stimulating hormone (FSH), in particular, a hypo-glycosylated form of FSH, as well as compositions and formulations including, nucleic acids encoding, cell lines expressing,...  
WO/2021/092543A1
Provided are methods for treating a disease, disorder, or condition associated with an acid ceramidase (AC) biological activity. The methods include administering to a subject in need thereof a composition including an AC inhibitor and a...  
WO/2021/092204A1
Methods and compositions related to a nucleic acid-guided nuclease cell targeting screen are provided. The invention relates to compositions and methods for identifying cell targeting proteins that, when associated with a nucleic acid-gu...  
WO/2021/092254A1
Disclosed here are phage compositions comprising Type I CRISPR-Cas systems and methods of use thereof. In some embodiments, disclosed herein is a nucleic acid sequence comprising (a) a first CRISPR array designed to be operable with a fi...  
WO/2021/090552A1
One embodiment of the present invention pertains to an enteric preparation containing milk-derived lactoferrin that has a lactoferrin monomer (A) peak area ratio of 62% or more and a low-molecular weight aggregate (B) peak area ratio of ...  
WO/2021/091560A1
The present disclosure concerns combination therapy for cancer that utilizes (i) an oncolytic virus; (ii) a virus comprising nucleic acid encoding an immunomodulatory factor; and (iii) at least one cell comprising a chimeric antigen rece...  
WO/2021/089875A1
The invention relates to novel derivatives of Interleukin-22 (IL-22), particularly those comprising a fatty acid covalently attached to an IL-22 protein, and their use in therapy.  
WO/2021/091511A2
The invention is related to conjugation of protein drugs with biopolymers by an enzymatic method and obtaining conjugates thereof and forming patch structures that comprises these conjugates.  
WO/2021/064250A3
An isolated or recombinant polypeptide is provided and comprises a sequence selected from the group comprising NI01, α1α2, α2α3, α3α4, α1α2α3, α2 α3 α4, R-NI01, NT-205, H16, H1M NI01-R, 3NH (α1α3α3), H1 (α1α2), H2 (α2α...  
WO/2021/090345A1
Composition for the treatment of intestinal gas and bloating, based on simethicone as an anti-foaming agent, acts on the symptoms of intestinal bloating and on the phenomena at its origin, thus preventing its formation. This allows to fu...  
WO/2021/090959A1
The present invention provides a substituted polypeptide having the effect of inhibiting MMP2 and represented by formula [I'], or a pharmaceutically acceptable salt thereof.  
WO/2021/091009A1
The present application discloses a method for screening an inflammatory bowel disease therapeutic agent on the basis of a mechanism in which RORα inhibits NF-κB transcriptional activity in the bowels, thereby inhibiting the expression...  
WO/2021/091899A1
The present disclosure provides an antibody that binds human Adhesion G Protein-Coupled Receptor B1 (BAI1) protein, compositions comprising the same, and use thereof in methods of detection, methods of diagnosis, and methods of treatment...  
WO/2021/092187A1
The present invention includes a method for detecting or predicting a disease or condition related to a ratio of luteinizing hormone to follicle-stimulating hormone (LH/FSH ratio) comprising: obtaining or having obtained a biological sam...  
WO/2021/089695A1
The present disclosure relates to a class of engineered polypeptides having a binding affinity for high mobility group box 1 protein (HMGB1), and provides an HMGB1 binding polypeptide comprising the sequence EX2X3X4AX6X7EIX10 X11LPNLX16X...  
WO/2021/091967A1
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.  
WO/2021/092130A1
This invention relates to recombinant nucleic constructs comprising Type V CRISPR-Cas effector proteins, reverse transcriptases and extended guide nucleic acids and methods of use thereof for modifying nucleic acids in plants. In a first...  
WO/2021/048779A3
The present invention provides a method of treating ocular disorders by administering a suitable amount of VEGF inhibitors in a patient in need thereof, wherein the suitable amount of VEGF inhibitor is determined with respect to the body...  
WO/2021/087561A1
The invention provides fusion proteins comprising a growth factor or cytokine and a syndecan binding peptide and the use of such fusion proteins in regenerative medicine, particularly in treating skin wounds, including diabetic wounds an...  
WO/2021/089678A1
The present invention relates to improved medical therapies for all forms and stages of dementia involving administration of (i) GLP-1 receptor agonists to subjects with metabolic syndrome or (ii) semaglutide.  
WO/2021/091541A1
A method is described to discover, identify, analyze, quantitate, and otherwise detect expression of and determine the amino acid sequence of cancer neoantigenic peptides directly from histopathologically-processed cancer patient tumor t...  
WO/2020/245783A3
A method and system for identification of target sites in protein coding regions for combating pathogens has been provided. The method relates to identifying a set of nucleotide repeat sequences that occur within the complete coding regi...  
WO/2021/088585A1
A parathyroid hormone 1-34 pharmaceutical composition and a preparation method thereof, specifically relating to a parathyroid hormone 1-34 pharmaceutical composition including parathyroid hormone 1-34 as an active ingredient and a pharm...  
WO/2021/092079A1
In certain aspects, the present disclosure relates to methods of treating systemic sclerosis (SSc) using ΤβRΙΙ antagonists comprising a heterologous domain and a truncated, ligand -binding portion of the extracellular domain of ΤβR...  
WO/2021/089752A1
The invention relates to pharmaceutical compositions comprising a GLP-1 agonist, an SLGT2 inhibitor, a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, and a hydrotrope. The invention further relates to processes for the preparation o...  
WO/2021/090069A1
The disclosure relates to methods for treating cancer. More particularly, the disclosure relates to use of chimeric non-natural synthetic proteins, in combination with non-tyrosine targeting kinase inhibitors (NTKIs), in treating cancer ...  
WO/2021/091310A1
The present invention relates to a novel human epidermal growth factor (hEGF) fusion protein and a use thereof. More specifically, the hEGF fusion protein of the present invention comprises: a Bacillus subtilis CH2-derived chitosanase si...  

Matches 1 - 50 out of 189,713